{ "run": { "id": "cmnr14mbn056bp6588xwdiaxz", "region": "US", "assetId": "cmnr14m9y0564p658na613j73", "ticker": "MRK", "snapshotId": "cmnr14mac0567p658uax94noy", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:25.758Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr14mac0567p658uax94noy", "assetId": "cmnr14m9y0564p658na613j73", "asOf": "2026-04-08T20:00:56.000Z", "snapshot": { "asOf": "2026-04-08T20:00:56.000Z", "quote": { "asOf": "2026-04-08T20:00:56.000Z", "open": null, "price": 123.18, "dayLow": 117.97, "volume": 7343366, "dayHigh": 123.63, "currency": "USD", "prevClose": 119.28, "week52Low": 73.31, "week52High": 125.14 }, "fundamentals": { "pe": 14.4191780821918, "beta": 0.292182327061782, "epsTTM": 7.3, "fcfTTM": 12142000000, "growth": { "epsYoy": 0.07988165680473373, "revenueYoy": 0.01313738935294851 }, "sector": "Pharmaceutical Preparations", "margins": { "net": 0.2807832520650351, "gross": null, "operating": null }, "website": "http://merck.com", "industry": "Pharmaceuticals", "pegRatio": 1.80506747843734, "ebitdaTTM": 28490000000, "forwardPe": 20.4785992217899, "marketCap": 198051000000, "totalCash": 13242000000, "totalDebt": 37111000000, "debtEquity": 0.937896817853477, "quickRatio": 0.5555594651653765, "revenueTTM": 65011000000, "companyName": "Merck & Co., Inc.", "priceToBook": 2.42641373146979, "currentRatio": 1.36460239268121, "dividendYield": 0.0313182856716717, "returnOnAssets": 0.1558758731405735, "returnOnEquity": 0.346994639394746, "analystOpinions": null, "businessSummary": "Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.", "enterpriseValue": 298134520000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 75000, "sharesOutstanding": 2472392003, "enterpriseToEbitda": 10.46453211653212, "analystTargetMedian": null, "enterpriseToRevenue": 4.58590884619526, "operatingCashflowTTM": 16472000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:25.716Z" }, "results": [ { "id": "cmnr14mbq056dp658dt7rnctf", "runId": "cmnr14mbn056bp6588xwdiaxz", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI_EQUITY_RESEARCH_v1\",\"as_of\":\"2026-04-08T20:00:56.000Z\",\"ticker\":\"MRK\",\"currency\":\"USD\",\"current_price\":123.18,\"target_price_6m\":127,\"target_price_12m\":130,\"recommendation\":\"HOLD\",\"confidence\":0.55,\"thesis_bullets\":[\"Keytruda franchise dominant but LOE overhang looms circa 2028\",\"Trailing PE of ~14.4x looks attractive but forward PE ~20.5x signals earnings drop\",\"Strong FCF of $12.1B supports dividends and pipeline reinvestment\",\"Low beta of 0.29 provides defensive portfolio characteristics\",\"Pipeline diversification is critical but execution risk remains elevated\"],\"key_drivers\":[{\"driver\":\"Keytruda revenue durability and subcutaneous formulation extension\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Approaching Keytruda loss of exclusivity (~2028) creating earnings cliff risk\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Late-stage pipeline readouts in oncology and immunology\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Modest 1.3% YoY revenue growth signaling franchise maturity\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Strong FCF generation supporting dividends and bolt-on M&A\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated debt/equity of 0.94 from prior acquisitions\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"IRA drug pricing reform creating pricing headwinds\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"3.1% dividend yield attractive for income-oriented investors\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Return on equity of 34.7% reflects efficient capital deployment\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Keytruda biosimilar competition post-2028 could erode 40%+ of revenue\",\"Late-stage pipeline clinical failures would undermine replacement thesis\",\"IRA Medicare negotiation expanding to more drugs pressures pricing\",\"Large M&A integration risk if pursuing transformative deals\",\"Competitive threats from novel oncology modalities (ADCs, bispecifics)\"],\"assumptions\":{\"revenue_cagr_3y\":0.03,\"ebit_margin_target\":0.32,\"wacc\":0.085,\"terminal_multiple\":12},\"scenarios\":{\"bear\":{\"target_price\":102,\"prob\":0.25,\"notes\":\"Keytruda cliff fears accelerate; pipeline setback compresses multiple to ~10x.\"},\"base\":{\"target_price\":130,\"prob\":0.50,\"notes\":\"Steady execution, modest growth; multiple holds near current ~12x EV/EBITDA.\"},\"bull\":{\"target_price\":155,\"prob\":0.25,\"notes\":\"Pipeline catalysts extend Keytruda franchise; multiple re-rates toward 14x.\"}},\"method_notes\":\"Blended EV/EBITDA and PE-based valuation anchored on snapshot fundamentals. Forward PE gap (14.4 trailing vs 20.5 forward) highlights expected earnings compression from Keytruda LOE. Probability-weighted 12M return ~4.9% with high uncertainty supports HOLD. Defensive beta and dividend yield offset by structural revenue cliff. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:56.000Z", "model": "AI_EQUITY_RESEARCH_v1", "risks": [ "Keytruda biosimilar competition post-2028 could erode 40%+ of revenue", "Late-stage pipeline clinical failures would undermine replacement thesis", "IRA Medicare negotiation expanding to more drugs pressures pricing", "Large M&A integration risk if pursuing transformative deals", "Competitive threats from novel oncology modalities (ADCs, bispecifics)" ], "ticker": "MRK", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution, modest growth; multiple holds near current ~12x EV/EBITDA.", "target_price": 130 }, "bear": { "prob": 0.25, "notes": "Keytruda cliff fears accelerate; pipeline setback compresses multiple to ~10x.", "target_price": 102 }, "bull": { "prob": 0.25, "notes": "Pipeline catalysts extend Keytruda franchise; multiple re-rates toward 14x.", "target_price": 155 } }, "confidence": 0.55, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.03, "terminal_multiple": 12, "ebit_margin_target": 0.32 }, "key_drivers": [ { "driver": "Keytruda revenue durability and subcutaneous formulation extension", "impact": "HIGH", "direction": "POS" }, { "driver": "Approaching Keytruda loss of exclusivity (~2028) creating earnings cliff risk", "impact": "HIGH", "direction": "NEG" }, { "driver": "Late-stage pipeline readouts in oncology and immunology", "impact": "HIGH", "direction": "POS" }, { "driver": "Modest 1.3% YoY revenue growth signaling franchise maturity", "impact": "MED", "direction": "NEG" }, { "driver": "Strong FCF generation supporting dividends and bolt-on M&A", "impact": "MED", "direction": "POS" }, { "driver": "Elevated debt/equity of 0.94 from prior acquisitions", "impact": "MED", "direction": "NEG" }, { "driver": "IRA drug pricing reform creating pricing headwinds", "impact": "MED", "direction": "NEG" }, { "driver": "3.1% dividend yield attractive for income-oriented investors", "impact": "LOW", "direction": "POS" }, { "driver": "Return on equity of 34.7% reflects efficient capital deployment", "impact": "MED", "direction": "POS" } ], "method_notes": "Blended EV/EBITDA and PE-based valuation anchored on snapshot fundamentals. Forward PE gap (14.4 trailing vs 20.5 forward) highlights expected earnings compression from Keytruda LOE. Probability-weighted 12M return ~4.9% with high uncertainty supports HOLD. Defensive beta and dividend yield offset by structural revenue cliff. Not investment advice.", "current_price": 123.18, "recommendation": "HOLD", "thesis_bullets": [ "Keytruda franchise dominant but LOE overhang looms circa 2028", "Trailing PE of ~14.4x looks attractive but forward PE ~20.5x signals earnings drop", "Strong FCF of $12.1B supports dividends and pipeline reinvestment", "Low beta of 0.29 provides defensive portfolio characteristics", "Pipeline diversification is critical but execution risk remains elevated" ], "target_price_6m": 127, "target_price_12m": 130 }, "errorsJson": { "attempts": [ { "error": "sanity_error: buy_scenario_return_too_low: BUY requires >= 6% return from probability-weighted scenarios.", "attempt": 0, "rawOutputTruncated": "{\"model\":\"AI_EQUITY_RESEARCH_v1\",\"as_of\":\"2026-04-08T20:00:56.000Z\",\"ticker\":\"MRK\",\"currency\":\"USD\",\"current_price\":123.18,\"target_price_6m\":129,\"target_price_12m\":132,\"recommendation\":\"BUY\",\"confidence\":0.57,\"thesis_bullets\":[\"Keytruda franchise still dominant but LOE overhang approaching 2028\",\"Attractive trailing PE of ~14.4x and 3.1% dividend yield support valuation\",\"Forward PE of ~20.5x signals market expects near-term earnings compression\",\"Pipeline diversification critical to offset Keytruda revenue cliff\",\"Low beta of 0.29 offers defensive characteristics in volatile markets\"],\"key_drivers\":[{\"driver\":\"Keytruda revenue durability and subcutaneous formulation potential\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Approaching Keytruda loss of exclusivity (~2028)\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Pipeline readouts in oncology and immunology\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Modest revenue growth (1.3% YoY) signaling maturity\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Strong FCF generation ($12.1B TTM) supports dividends and M&A\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated debt/equity of 0.94 from acquisitions\",\"impact\":\"MED\",\"direction…" } ], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 31125, "createdAt": "2026-04-09T05:21:25.758Z", "usage": { "inputTokens": 4210, "outputTokens": 1793, "costUsd": 0.065875 } }, { "id": "cmnr14mbq056gp658p5o7s389", "runId": "cmnr14mbn056bp6588xwdiaxz", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:56.000Z\",\n \"ticker\": \"MRK\",\n \"currency\": \"USD\",\n \"current_price\": 123.18,\n \"target_price_6m\": 124.0,\n \"target_price_12m\": 125.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Strong oncology pipeline supports growth.\",\n \"High profitability with solid margins.\",\n \"Revenue growth is slowing significantly.\",\n \"Valuation is fair compared to peers.\",\n \"Mixed evidence with balanced risks.\"\n ],\n \"key_drivers\": [\n {\"driver\": \"Keytruda sales performance\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Pipeline drug approvals\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Patent expirations\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Competitive intensity\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Cost efficiency measures\", \"impact\": \"LOW\", \"direction\": \"POS\"},\n {\"driver\": \"Global demand for pharmaceuticals\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Regulatory environment\", \"impact\": \"MED\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\n \"Patent cliffs for key drugs\",\n \"Regulatory approval delays\",\n \"Pricing pressure in healthcare\",\n \"Economic downturn\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.03,\n \"ebit_margin_target\": 0.30,\n \"wacc\": 0.08,\n \"terminal_multiple\": 20\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 115.0, \"prob\": 0.3, \"notes\": \"Multiple contraction and weak pipeline.\"},\n \"base\": {\"target_price\": 125.0, \"prob\": 0.5, \"notes\": \"Moderate growth and stable multiples.\"},\n \"bull\": {\"target_price\": 135.0, \"prob\": 0.2, \"notes\": \"Strong pipeline success and multiple expansion.\"}\n },\n \"method_notes\": \"Valuation based on forward earnings multiple and growth assumptions; not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:56.000Z", "model": "AI Equity Research Model", "risks": [ "Patent cliffs for key drugs", "Regulatory approval delays", "Pricing pressure in healthcare", "Economic downturn" ], "ticker": "MRK", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth and stable multiples.", "target_price": 125 }, "bear": { "prob": 0.3, "notes": "Multiple contraction and weak pipeline.", "target_price": 115 }, "bull": { "prob": 0.2, "notes": "Strong pipeline success and multiple expansion.", "target_price": 135 } }, "confidence": 0.6, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.03, "terminal_multiple": 20, "ebit_margin_target": 0.3 }, "key_drivers": [ { "driver": "Keytruda sales performance", "impact": "HIGH", "direction": "POS" }, { "driver": "Pipeline drug approvals", "impact": "HIGH", "direction": "POS" }, { "driver": "Patent expirations", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive intensity", "impact": "MED", "direction": "NEG" }, { "driver": "Cost efficiency measures", "impact": "LOW", "direction": "POS" }, { "driver": "Global demand for pharmaceuticals", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory environment", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation based on forward earnings multiple and growth assumptions; not investment advice.", "current_price": 123.18, "recommendation": "HOLD", "thesis_bullets": [ "Strong oncology pipeline supports growth.", "High profitability with solid margins.", "Revenue growth is slowing significantly.", "Valuation is fair compared to peers.", "Mixed evidence with balanced risks." ], "target_price_6m": 124, "target_price_12m": 125 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 475, "createdAt": "2026-04-09T05:21:25.758Z", "usage": { "inputTokens": 2081, "outputTokens": 4290, "costUsd": 0.002384 } }, { "id": "cmnr14mbq056ep658t2ia4aaf", "runId": "cmnr14mbn056bp6588xwdiaxz", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research Analyst AI\",\n \"as_of\": \"2026-04-08T20:00:56.000Z\",\n \"ticker\": \"MRK\",\n \"currency\": \"USD\",\n \"current_price\": 123.18,\n \"target_price_6m\": 131.00,\n \"target_price_12m\": 138.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.72,\n \"thesis_bullets\": [\n \"Keytruda remains the dominant oncology therapy with sustained market share and label expansions.\",\n \"Winrevair launch provides a significant new revenue stream to mitigate upcoming patent cliffs.\",\n \"Strong Animal Health franchise offers high-margin, non-cyclical cash flows and diversification.\",\n \"Robust dividend yield and low beta provide defensive characteristics in volatile markets.\",\n \"Strategic M&A pipeline integration is successfully addressing the 2028 Keytruda loss of exclusivity.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Keytruda label expansion\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Winrevair commercial uptake\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Gardasil demand in China\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"IRA drug price negotiations\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Animal Health margin stability\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Pipeline M&A execution\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Keytruda patent expiration in 2028\",\n \"US drug pricing legislation impacts\",\n \"Clinical trial failures for pipeline candidates\",\n \"Competition from biosimilars and new oncology entrants\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.045,\n \"ebit_margin_target\": 0.40,\n \"wacc\": 0.075,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 110.00,\n \"prob\": 0.2,\n \"notes\": \"Faster Keytruda erosion and significant IRA pricing headwinds.\"\n },\n \"base\": {\n \"target_price\": 138.00,\n \"prob\": 0.6,\n \"notes\": \"Steady pipeline execution and successful Winrevair launch.\"\n },\n \"bull\": {\n \"target_price\": 155.00,\n \"prob\": 0.2,\n \"notes\": \"Major pipeline breakthroughs and accretive M&A outperformance.\"\n }\n },\n \"method_notes\": \"Valuation uses a 17.5x P/E multiple on projected forward earnings. Note: Snapshot PE (14.4) and Price/EPS (16.8) show minor variance; used snapshot price as the primary baseline. Recommendation reflects ~12% upside potential and strong dividend support, qualifying as a BUY under the rubric. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:56.000Z", "model": "Equity Research Analyst AI", "risks": [ "Keytruda patent expiration in 2028", "US drug pricing legislation impacts", "Clinical trial failures for pipeline candidates", "Competition from biosimilars and new oncology entrants" ], "ticker": "MRK", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady pipeline execution and successful Winrevair launch.", "target_price": 138 }, "bear": { "prob": 0.2, "notes": "Faster Keytruda erosion and significant IRA pricing headwinds.", "target_price": 110 }, "bull": { "prob": 0.2, "notes": "Major pipeline breakthroughs and accretive M&A outperformance.", "target_price": 155 } }, "confidence": 0.72, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.045, "terminal_multiple": 15, "ebit_margin_target": 0.4 }, "key_drivers": [ { "driver": "Keytruda label expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Winrevair commercial uptake", "impact": "HIGH", "direction": "POS" }, { "driver": "Gardasil demand in China", "impact": "MED", "direction": "POS" }, { "driver": "IRA drug price negotiations", "impact": "HIGH", "direction": "NEG" }, { "driver": "Animal Health margin stability", "impact": "LOW", "direction": "POS" }, { "driver": "Pipeline M&A execution", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation uses a 17.5x P/E multiple on projected forward earnings. Note: Snapshot PE (14.4) and Price/EPS (16.8) show minor variance; used snapshot price as the primary baseline. Recommendation reflects ~12% upside potential and strong dividend support, qualifying as a BUY under the rubric. Not investment advice.", "current_price": 123.18, "recommendation": "BUY", "thesis_bullets": [ "Keytruda remains the dominant oncology therapy with sustained market share and label expansions.", "Winrevair launch provides a significant new revenue stream to mitigate upcoming patent cliffs.", "Strong Animal Health franchise offers high-margin, non-cyclical cash flows and diversification.", "Robust dividend yield and low beta provide defensive characteristics in volatile markets.", "Strategic M&A pipeline integration is successfully addressing the 2028 Keytruda loss of exclusivity." ], "target_price_6m": 131, "target_price_12m": 138 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-flash-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 19192, "createdAt": "2026-04-09T05:21:25.758Z", "usage": { "inputTokens": 2423, "outputTokens": 833, "costUsd": 0.014842 } }, { "id": "cmnr14mbq056cp658t2ueaj1b", "runId": "cmnr14mbn056bp6588xwdiaxz", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:56.000Z\",\"ticker\":\"MRK\",\"currency\":\"USD\",\"current_price\":123.18,\"target_price_6m\":127.8,\"target_price_12m\":129.0,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"Keytruda cash flows still underpin earnings despite moderating topline growth.\",\"Winrevair, vaccines, and animal health can diversify growth beyond oncology.\",\"Low beta, strong FCF, and dividend support downside resilience.\",\"Shares now trade near fair value after a strong rebound.\",\"Patent concentration and pipeline execution keep long-term uncertainty elevated.\"],\"key_drivers\":[{\"driver\":\"Keytruda durability\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Winrevair launch ramp\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Gardasil China normalization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Animal Health momentum\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Late-decade patent cliff\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Pipeline readout execution\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"IRA/global pricing pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Business development discipline\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Faster-than-expected Keytruda erosion\",\"Winrevair or pipeline disappointments\",\"Pricing reform and reimbursement pressure\",\"Gardasil demand volatility in China\",\"Acquisitions dilute returns or raise leverage\"],\"assumptions\":{\"revenue_cagr_3y\":0.045,\"ebit_margin_target\":0.36,\"wacc\":0.08,\"terminal_multiple\":13},\"scenarios\":{\"bear\":{\"target_price\":105,\"prob\":0.2,\"notes\":\"Pipeline slips and Keytruda concentration weighs on valuation.\"},\"base\":{\"target_price\":129,\"prob\":0.55,\"notes\":\"Core oncology stays resilient while new products offset slower vaccine growth.\"},\"bull\":{\"target_price\":147,\"prob\":0.25,\"notes\":\"Winrevair outperforms and pipeline execution supports multiple expansion.\"}},\"method_notes\":\"Base target uses a blend of discounted operating cash flow and terminal multiple based on the stated assumptions and snapshot fundamentals. Mixed growth outlook and fair valuation imply only modest 12M upside, below BUY threshold, so HOLD. No sell-side targets used; snapshot quote fields kept authoritative. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:56.000Z", "model": "AI Model Recommendation v2", "risks": [ "Faster-than-expected Keytruda erosion", "Winrevair or pipeline disappointments", "Pricing reform and reimbursement pressure", "Gardasil demand volatility in China", "Acquisitions dilute returns or raise leverage" ], "ticker": "MRK", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Core oncology stays resilient while new products offset slower vaccine growth.", "target_price": 129 }, "bear": { "prob": 0.2, "notes": "Pipeline slips and Keytruda concentration weighs on valuation.", "target_price": 105 }, "bull": { "prob": 0.25, "notes": "Winrevair outperforms and pipeline execution supports multiple expansion.", "target_price": 147 } }, "confidence": 0.63, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.045, "terminal_multiple": 13, "ebit_margin_target": 0.36 }, "key_drivers": [ { "driver": "Keytruda durability", "impact": "HIGH", "direction": "POS" }, { "driver": "Winrevair launch ramp", "impact": "HIGH", "direction": "POS" }, { "driver": "Gardasil China normalization", "impact": "MED", "direction": "POS" }, { "driver": "Animal Health momentum", "impact": "LOW", "direction": "POS" }, { "driver": "Late-decade patent cliff", "impact": "HIGH", "direction": "NEG" }, { "driver": "Pipeline readout execution", "impact": "HIGH", "direction": "POS" }, { "driver": "IRA/global pricing pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Business development discipline", "impact": "MED", "direction": "POS" } ], "method_notes": "Base target uses a blend of discounted operating cash flow and terminal multiple based on the stated assumptions and snapshot fundamentals. Mixed growth outlook and fair valuation imply only modest 12M upside, below BUY threshold, so HOLD. No sell-side targets used; snapshot quote fields kept authoritative. not investment advice", "current_price": 123.18, "recommendation": "HOLD", "thesis_bullets": [ "Keytruda cash flows still underpin earnings despite moderating topline growth.", "Winrevair, vaccines, and animal health can diversify growth beyond oncology.", "Low beta, strong FCF, and dividend support downside resilience.", "Shares now trade near fair value after a strong rebound.", "Patent concentration and pipeline execution keep long-term uncertainty elevated." ], "target_price_6m": 127.8, "target_price_12m": 129 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0660cf2791efe2f50069d75b71bb988190bc8e8806ac1e7139", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 49609, "createdAt": "2026-04-09T05:21:25.758Z", "usage": { "inputTokens": 2352, "outputTokens": 2775, "costUsd": 0.042966 } }, { "id": "cmnr14mbq056fp658dlx24kpg", "runId": "cmnr14mbn056bp6588xwdiaxz", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Pharma DCF Model\",\n \"as_of\": \"2026-04-08T20:00:56.000Z\",\n \"ticker\": \"MRK\",\n \"currency\": \"USD\",\n \"current_price\": 123.18,\n \"target_price_6m\": 130,\n \"target_price_12m\": 142,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Keytruda maintains strong sales momentum with new indications.\",\n \"Pipeline advancements in oncology enhance growth prospects.\",\n \"Patent expirations post-2028 create revenue headwinds.\",\n \"Strong cash flows support dividend and R&D investment.\",\n \"Current valuation offers moderate upside with risks balanced.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Keytruda performance\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"New drug approvals\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Keytruda patent cliff\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"R&D pipeline productivity\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Drug pricing pressures\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A execution success\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competition from biosimilars\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Keytruda patent expiration in 2028\",\n \"Clinical trial failures or delays\",\n \"Intense competition in oncology\",\n \"Regulatory hurdles for new drugs\",\n \"Rising debt from acquisitions\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.35,\n \"wacc\": 0.085,\n \"terminal_multiple\": 16\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 105,\n \"prob\": 0.25,\n \"notes\": \"Patent cliff and trial failures reduce revenues.\"\n },\n \"base\": {\n \"target_price\": 142,\n \"prob\": 0.55,\n \"notes\": \"Steady pipeline delivery meets expectations.\"\n },\n \"bull\": {\n \"target_price\": 175,\n \"prob\": 0.2,\n \"notes\": \"Breakthrough therapies accelerate revenue growth.\"\n }\n },\n \"method_notes\": \"3y DCF with 5% rev CAGR, 35% EBIT target, 8.5% WACC, 16x terminal. 15% expected 12M return supports BUY. Consensus not used for targets. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:56.000Z", "model": "AI Pharma DCF Model", "risks": [ "Keytruda patent expiration in 2028", "Clinical trial failures or delays", "Intense competition in oncology", "Regulatory hurdles for new drugs", "Rising debt from acquisitions" ], "ticker": "MRK", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady pipeline delivery meets expectations.", "target_price": 142 }, "bear": { "prob": 0.25, "notes": "Patent cliff and trial failures reduce revenues.", "target_price": 105 }, "bull": { "prob": 0.2, "notes": "Breakthrough therapies accelerate revenue growth.", "target_price": 175 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 16, "ebit_margin_target": 0.35 }, "key_drivers": [ { "driver": "Keytruda performance", "impact": "HIGH", "direction": "POS" }, { "driver": "New drug approvals", "impact": "HIGH", "direction": "POS" }, { "driver": "Keytruda patent cliff", "impact": "HIGH", "direction": "NEG" }, { "driver": "R&D pipeline productivity", "impact": "MED", "direction": "POS" }, { "driver": "Drug pricing pressures", "impact": "MED", "direction": "NEG" }, { "driver": "M&A execution success", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Competition from biosimilars", "impact": "MED", "direction": "NEG" } ], "method_notes": "3y DCF with 5% rev CAGR, 35% EBIT target, 8.5% WACC, 16x terminal. 15% expected 12M return supports BUY. Consensus not used for targets. Not investment advice.", "current_price": 123.18, "recommendation": "BUY", "thesis_bullets": [ "Keytruda maintains strong sales momentum with new indications.", "Pipeline advancements in oncology enhance growth prospects.", "Patent expirations post-2028 create revenue headwinds.", "Strong cash flows support dividend and R&D investment.", "Current valuation offers moderate upside with risks balanced." ], "target_price_6m": 130, "target_price_12m": 142 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "872b7709-359e-9966-a0db-cd66ce090d83", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 17274, "createdAt": "2026-04-09T05:21:25.758Z", "usage": { "inputTokens": 2692, "outputTokens": 3306, "costUsd": 0.057666 } } ] } }